Case | HBS Case Collection | January 2001

Abgenix and the XenoMouse

by Robert J. Dolan

Abstract

Abgenix has a unique method for generating antibodies useful in treating a number of diseases, including cancer. In early 2000, the company's cancer has performed very well in animal testing and is moving to early stage human testing. Abgenix must decide whether to sell the product development program to a large pharmaceutical company or to enter into a joint venture to push the product ahead.

Keywords: Product Development; Marketing Strategy; Health Testing and Trials; Risk and Uncertainty; Technological Innovation; Innovation Strategy; Science-Based Business; Biotechnology Industry;

Citation:

Dolan, Robert J. "Abgenix and the XenoMouse." Harvard Business School Case 501-061, January 2001.